[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
E Kyriazopoulou, G Poulakou, H Milionis… - Nature …, 2021 - europepmc.org
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
E Kyriazopoulou, G Poulakou, H Milionis… - Nature …, 2021 - ncbi.nlm.nih.gov
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[PDF][PDF] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - 2021 - repository.ubn.ru.nl
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - Nature Medicine, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Early increase of soluble urokinase
plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of …
plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
E Kyriazopoulou, G Poulakou, H Milionis… - Nature Medicine, 2021 - go.gale.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis… - NATURE …, 2021 - iris.unibs.it
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
E Kyriazopoulou, G Poulakou, H Milionis… - Nature …, 2021 - journalwise.acponline.org
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - 2021 - cabidigitallibrary.org
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis… - NATURE …, 2021 - iris.unisr.it
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …